Project Grant R21AR083662
- Federal Grant Award Summary Cincinnati Children's Hospital Medical Center received a $451,250 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), awarded May 8, 2025, with completion targeted for March 31, 2030. The award supports fundamental research investigating the molecular basis of circadian and sensory integration in neuronal clocks, specifically examining how the central pacemaker in...
- Federal Project Grant Award Summary The California Institute of Technology received a $1.87M Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective March 1, 2026 through February 28, 2030. The award supports fundamental research to elucidate the molecular mechanisms underlying the mammalian circadian clock through three integrated research objectives: (1) mapping the complete protein...
- This Project Grant award of $109,076, issued March 3, 2026, supports research under the National Institute on Aging's Aging Research program (CFDA 93.866). The research, conducted at Weill Medical College of Cornell University in New York, investigates vulnerable cell populations in aging-induced circadian clock remodeling and disruption through high-throughput single-nucleus RNA sequencing (snRNA-seq) of flash-frozen tissues from mice. The primary deliverables include comprehensive...
- The federal Project Grant award R21NS136974 was provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The $466,125 award to President and Fellows of Harvard College, doing business as Harvard Medical School, aims to analyze the composition of two BMAL1 circadian clock complexes purified from the mammalian brain and develop procedures for determining their...
- This Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) supports biomedical research investigating the epigenetic basis of glucocorticoid action on pancreatic beta cells. Awarded to Mayo Clinic Arizona in the amount of $807,446 for the period February 1, 2026, through January 31, 2031, the research combines transcriptional, epigenetic, multi-omic, and...
- Federal Project Grant Award Summary The University of Cincinnati's Sponsored Research Services Division received a $380,089 Project Grant award dated September 10, 2025, from the National Institute of General Medical Sciences under the Biomedical Research and Research Training program (CFDA 93.859). The grant funds fundamental research into the molecular mechanisms governing circadian rhythms through September 2029. The project combines mathematical modeling, statistical uncertainty...
- Grant Award Summary The University of Massachusetts Medical School received a $2,263,740 Project Grant from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), awarded March 1, 2025, with a completion date of February 28, 2029. This research project focuses on developing and optimizing synthetic RNA switch technology—specifically the T3H38 ribozyme—to enable...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded $134,982.00 to The Regents of the University of California, San Francisco under the Cardiovascular Diseases Research program (CFDA 93.837) on September 5, 2025, with a completion date of June 30, 2027. This project grant supports research investigating the genetic and nutritional control of sleep across seasons, with particular focus on how circadian clock mechanisms regulate the adaptation of sleep and...
- This $162,512 Project Grant award from the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865) will support research to examine how the circadian clock influences reproductive behavior and sexual drive in mice. The project, conducted by the Beth Israel Deaconess Medical Center, Inc. (Bidmc) in Boston, MA, aims to determine if the timing of peak sexual behavior between males and females impacts...
- This $295,128 Project Grant award from the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research (CFDA 93.865) program supports the development and feasibility testing of an app-based Circadian Synchronization Therapy with Light (CST-L) intervention for pregnant women. The goal is to create a mobile application for iOS and Android that can help improve maternal mood, health, and infant sleep by optimizing circadian...
SYNTHETIC CHRONOGENETIC GENE CIRCUITS FOR CIRCADIAN CELL THERAPIES - ABSTRACT THE GOAL OF THIS PROJECT WILL BE TO COMBINE PRINCIPLES OF SYNTHETIC BIOLOGY, TISSUE ENGINEERING, AND CIRCADIAN BIOLOGY TO GENERATE LIVING STEM CELL-BASED IMPLANTS THAT CAN DELIVER BIOLOGIC DRUGS IN A PRESCRIBED CIRCADIAN MANNER FOR THE TREATMENT OF A WIDE RANGE OF DISEASE PROCESSES THAT EXHIBIT DIURNAL RHYTHMICITY. TO ENGINEER THIS REGULATORY SYSTEM, THE CORE CLOCK GENE CIRCUITRY OF MURINE INDUCED PLURIPOTENT STEM CELLS (IPSCS) WILL BE ENGINEERED TO SYNTHESIZE ANTI-CYTOKINE BIOLOGIC DRUGS. THESE CELLS WILL BE USED TO FORM TISSUE-ENGINEERED CONSTRUCTS FOR IN VITRO AND IN VIVO TESTING. THE FIRST AIM OF THIS PROJECT WILL FOCUS ON THE CREATION OF SYNTHETIC "CHRONOGENETIC" GENE CIRCUITS WITH PRESCRIBED FREQUENCY, PHASE, AND AMPLITUDE OF BIOLOGIC DRUG DELIVERY. MORE SPECIFICALLY, CELLS WILL BE DESIGNED TO SYNTHESIZE INHIBITORS OF EITHER INTERLEUKIN 1 OR TUMOR NECROSIS FACTOR ALPHA. THESE CELLS WILL BE ENGINEERED INTO STABLE CARTILAGE CONSTRUCTS IN INJECTABLE HYDROGEL CARRIERS THAT WILL BE TESTED AS A THERAPEUTIC APPROACH FOR THE TREATMENT OF EXPERIMENTAL RHEUMATOID ARTHRITIS (RA) IN TWO DIFFERENT MOUSE MODELS OF THIS DISEASE. RA IS AN INFLAMMATORY DISEASE THAT AFFECTS APPROXIMATELY 1% OF THE GENERAL POPULATION. SEVERAL ANTI-CYTOKINE BIOLOGICS ARE CURRENTLY IN CLINICAL USE; HOWEVER, THE CONTINUOUS ADMINISTRATION OF THESE THERAPEUTICS AT HIGH LEVEL CAN LEAD TO SIGNIFICANT ADVERSE EFFECTS. WE POSIT THAT DRUG DELIVERY THAT ALIGNS WITH THE CIRCADIAN RHYTHMICITY OF PEAK INFLAMMATORY CYTOKINE RELEASE WILL HAVE SIGNIFICANTLY IMPROVED EFFECTIVENESS. THE EFFICACY OF THESE APPROACHES WILL BE ASSESSED USING CLINICAL, HISTOLOGIC, MOLECULAR, AND PAIN/BEHAVIOR TESTING. THE CREATION OF SUCH SYNTHETIC CHRONOGENETIC SYSTEMS CELLS PROVIDES THE POSSIBILITY FOR LONG-TERM "CHRONOTHERAPY", OR TIMED DRUG DELIVERY FOR THE TREATMENT OF MANY CHRONIC INFLAMMATORY DISEASES BEYOND RA.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 8/18/25 | ||
| Not listed | $376.3k | 9/20/23 |